These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 38505276)

  • 1. Cardiovascular consequences of sickle cell disease.
    Palomarez A; Jha M; Medina Romero X; Horton RE
    Biophys Rev (Melville); 2022 Sep; 3(3):031302. PubMed ID: 38505276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.
    Nader E; Conran N; Romana M; Connes P
    Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults.
    Cooper TE; Hambleton IR; Ballas SK; Johnston BA; Wiffen PJ
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry.
    Rab MAE; van Oirschot BA; Bos J; Kanne CK; Sheehan VA; van Beers EJ; van Wijk R
    J Vis Exp; 2019 Nov; (153):. PubMed ID: 31762454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
    Nader E; Romana M; Connes P
    Front Immunol; 2020; 11():454. PubMed ID: 32231672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities.
    Alramadhani D; Aljahdali AS; Abdulmalik O; Pierce BD; Safo MK
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and environmental contributors to neurological complications in sickle cell disease.
    Karkoska KA; Gollamudi J; Hyacinth HI
    Exp Biol Med (Maywood); 2023 Aug; 248(15):1319-1332. PubMed ID: 37688519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice.
    Yalamanoglu A; Dubach IL; Schulthess N; Ingoglia G; Swindle DC; Humar R; Schaer DJ; Buehler PW; Irwin DC; Vallelian F
    Front Immunol; 2021; 12():627944. PubMed ID: 33763072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophisiology of sickle cell disease and new drugs for the treatment.
    De Franceschi L
    Mediterr J Hematol Infect Dis; 2009 Dec; 1(1):e2009024. PubMed ID: 21415994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sickle Cell Disease in Brazil: Current Management.
    da Silva Araújo A; Silva Pinto AC; de Castro Lobo CL; Figueiredo MS; Menosi Gualandro SF; Olalla Saad ST; Cançado RD
    Hemoglobin; 2024 Apr; ():1-13. PubMed ID: 38663998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical review of therapeutic interventions in sickle cell disease: Progress and challenges.
    Ala C; Joshi RP; Gupta P; Goswami SG; Ramalingam S; Kondapalli Venkata Gowri CS; Sankaranarayanan M
    Arch Pharm (Weinheim); 2024 Jul; ():e2400381. PubMed ID: 39031925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sickle cell disease as a vascular disorder.
    Ofori-Acquah SF
    Expert Rev Hematol; 2020 Jun; 13(6):645-653. PubMed ID: 32362160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizanlizumab in sickle cell disease.
    Kaur K; Kennedy K; Liles D
    Pain Manag; 2023 Oct; ():. PubMed ID: 37850353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sickle cell diseases: What can nuclear medicine offer?
    Niccoli Asabella A; Altini C; Nappi AG; Lavelli V; Ferrari C; Marzullo A; Loiodice A; Rubini G
    Hell J Nucl Med; 2019; 22(1):2-3. PubMed ID: 30843001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative intravital two-photon excitation microscopy reveals absence of pulmonary vaso-occlusion in unchallenged Sickle Cell Disease mice.
    Bennewitz MF; Watkins SC; Sundd P
    Intravital; 2014 Jul; 3(2):e29748. PubMed ID: 25995970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular Vesicles in Sickle Cell Disease: Plasma Concentration, Blood Cell Types Origin Distribution and Biological Properties.
    Nader E; Garnier Y; Connes P; Romana M
    Front Med (Lausanne); 2021; 8():728693. PubMed ID: 34490315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiomyopathy in Sickle Cell Disease.
    Kaur H; Aurif F; Kittaneh M; Chio JPG; Malik BH
    Cureus; 2020 Aug; 12(8):e9619. PubMed ID: 32923220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microfluidics in Sickle Cell Disease Research: State of the Art and a Perspective Beyond the Flow Problem.
    Aich A; Lamarre Y; Sacomani DP; Kashima S; Covas DT; de la Torre LG
    Front Mol Biosci; 2020; 7():558982. PubMed ID: 33763448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The APC-EPCR-PAR1 axis in sickle cell disease.
    Ramadas N; Sparkenbaugh EM
    Front Med (Lausanne); 2023; 10():1141020. PubMed ID: 37497271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autonomic nervous system involvement in sickle cell disease.
    Coates TD; Chalacheva P; Zeltzer L; Khoo MCK
    Clin Hemorheol Microcirc; 2018; 68(2-3):251-262. PubMed ID: 29614636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.